within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF03_Upadacitinib;

model Upadacitinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.79,
    Cl = 6.527777777777778e-06,
    adminDuration = 600,
    adminMass = 15 / 1000000,
    adminCount = 1,
    Vd = 0.294,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.021666666666666667,
    Tlag = 18.0,
    Vdp = 0.234,
    k12 = 1.4777777777777778e-05,
    k21 = 1.4777777777777778e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Upadacitinib</td></tr><tr><td>ATC code:</td><td>L04AF03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>15</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>294</td><td>L</td></tr>
    <tr><td>clearance:</td><td>23.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and other inflammatory disorders. It is approved for use in several countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration in adult healthy subjects; population PK based on phase I and phase III studies.</p><h4>References</h4><ol><li><p>Ponce-Bobadilla, AV, et al., &amp; Mohamed, MF (2023). Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. <i>Clinical pharmacokinetics</i> 62(1) 101–112. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01191-6\">10.1007/s40262-022-01191-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36571701/\">https://pubmed.ncbi.nlm.nih.gov/36571701</a></p></li><li><p>Klünder, B, et al., &amp; Othman, AA (2018). Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. <i>Clinical pharmacokinetics</i> 57(8) 977–988. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0605-6\">10.1007/s40262-017-0605-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29076110/\">https://pubmed.ncbi.nlm.nih.gov/29076110</a></p></li><li><p>Klünder, B, et al., &amp; Othman, AA (2019). Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. <i>Clinical pharmacokinetics</i> 58(8) 1045–1058. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00739-3\">10.1007/s40262-019-00739-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30945116/\">https://pubmed.ncbi.nlm.nih.gov/30945116</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AF03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Upadacitinib;
